SCHEMBL201572

SCHEMBL201572

CCCc1ccc(-c2ccc(C(=O)NC(CCS(C)(=O)=O)C(=O)NOCc3ccccc3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
CTSB P07858 3/20 0.44
CTSS P25774 2/20 0.44
CTSK P43235 2/20 0.44
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
KLKB1 P03952 1/20 0.43
HPGDS O60760 1/20 0.43
CA1 P00915 3/20 0.42
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42
CTSL P07711 1/20 0.42
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
F10 P00742 2/20 0.41
CA2 P00918 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203657 0.91 L3MBTL1 (0.50) L3MBTL1NPC1RAB9ACTSBCTSS
SCHEMBL2692848 0.82 TAS1R3 (0.51) L3MBTL1NPC1RAB9ACTSSTAS1R3
SCHEMBL200992 0.82 TAS1R3 (0.51) L3MBTL1NPC1RAB9ACTSSTAS1R3
SCHEMBL201383 0.82 CA2 (0.52) L3MBTL1NPC1RAB9ATAS1R3TAS1R1
SCHEMBL200816 0.80 TAS1R3 (0.63) L3MBTL1NPC1RAB9ACTSSTAS1R3
SCHEMBL203618 0.74 TAS1R3 (0.51) L3MBTL1NPC1RAB9ATAS1R3TAS1R1
SCHEMBL201362 0.73 TAS1R3 (0.65) L3MBTL1NPC1RAB9ACTSSTAS1R3
SCHEMBL2692891 0.73 TAS1R3 (0.52) L3MBTL1NPC1RAB9ACTSBCTSS
SCHEMBL202853 0.73 TAS1R3 (0.52) L3MBTL1NPC1RAB9ACTSBCTSS
SCHEMBL13821937 0.69 L3MBTL1 (0.60) L3MBTL1NPC1RAB9ACTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 L3MBTL1 2179/4885NPC1 1027/4885RAB9A 940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.